3-Cyclohexyl-N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-alanyl-N-(4-methyl-2-oxo-2H-chromen-7-yl)-L-lysinamide | 475115-35-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-Cyclohexyl-N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-alanyl-N-(4-methyl-2-oxo-2H-chromen-7-yl)-L-lysinamide
• 英文别名: 9H-fluoren-9-ylmethyl N-[1-[[6-amino-1-[(4-methyl-2-oxochromen-7-yl)amino]-1-oxohexan-2-yl]amino]-3-cyclohexyl-1-oxopropan-2-yl]carbamate
• CAS: 475115-35-6
• 化学式: C₄₀H₄₆N₄O₆
• 分子量: 678.8
• InChiKey: IKNOZZKXIDSTRN-UHFFFAOYSA-N

物化性质

• 沸点：
  937.5±65.0 °C(Predicted)
• 密度：
  1.242±0.06 g/cm3(Predicted)
• 溶解度：
  不溶于水

计算性质

• 辛醇/水分配系数(LogP)：
  6.5
• 重原子数：
  50
• 可旋转键数：
  14
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  149
• 氢给体数：
  4
• 氢受体数：
  7

安全信息

• WGK Germany：
  3

文献信息

• Non-natural galanin receptor ligands
  申请人：Kemia, Inc.

  公开号：US20030055000A1

  公开（公告）日：2003-03-20

  Compounds which are non-natural galanin receptor ligands are disclosed. The ligands are of small size, have agonist or antagonist galanin activity and may cross the blood-brain barrier to displace galanin from galanin receptors. The ligands are useful as medicaments for treatment of convulsions (e.g. in epilepsy), diseases and disorders related to endocrinology (e.g., growth hormone, insulin or prolactin release), tumors expressing galanin receptors, feeding disorders pain, allodynia, psychiatric disorders such as depression (involving e.g., noradrenaline or serotonin), cognitive disorders (e.g.. Alzeimer's disease), and the like.

  本研究公开了非天然加兰宁受体配体化合物。这些配体体积小，具有激动剂或拮抗剂 galanin 活性，并可穿过血脑屏障，将 galanin 从 galanin 受体中置换出来。这些配体可用作治疗下列疾病的药物：抽搐（如癫痫）、与内分泌有关的疾病和紊乱（如生长激素、胰岛素或催乳素释放）、表达加兰宁受体的肿瘤、进食障碍性疼痛、异动症、精神疾病如抑郁症（涉及去甲肾上腺素或血清素）、认知障碍（如阿尔茨海默病）等。
• US6747060B2
  申请人：——

  公开号：US6747060B2

  公开（公告）日：2004-06-08
• [EN] NON-NATURAL GALANIN RECEPTOR LIGANDS<br/>[FR] LIGANDS NON NATURELS DU RECEPTEUR DE LA GALANINE
  申请人：KEMIA INC

  公开号：WO2002096934A1

  公开（公告）日：2002-12-05

  Compounds which are non-natural galanin receptor ligands are disclosed. The ligands are of small size, have agonist or antagonist galanin activity and may cross the blood-brain barrier to displace galanin receptors. The ligands are useful as medicaments for treatment of convulsions (e.g. in epilepsy), diseases and disorders related to endocrinology (e.g., growth hormone, insulin or prolactin release), tumors expressing galanin receptors, feeding disorders pain, allodynia, psychiatric disorders such as depression (involving e.g., noradrenaline or serotonin), cognitive disorders (e.g. Alzeimer's disease), and the like.
• [EN] PEPTIDOMIMETIC GALANIN RECEPTOR MODULATORS<br/>[FR] MODULATEURS DES RÉCEPTEURS À LA GALANINE PEPTIDOMIMÉTIQUES
  申请人：ROBERTS EDWARD

  公开号：WO2012009258A2

  公开（公告）日：2012-01-19

  Potent and effective modulators of galanin receptors such as Ga1R1 and Ga1R2 are provided. Methods of preparation and methods of use are further provided. The compounds of the invention may be effective for treatment of malconditions in human patients including epilepsy or seizure disorders, mood disorders including depression and anxiety spectrum disorders; drug addiction including addiction to alcohol or tobacco; autistic spectrum diseases and pervasive development disorders; Alzheimer's disease or other dementias; cognition disorders; cerebral or myocardial stroke; demyelinating diseases including multiple sclerosis, Guillain-Barre syndrome and Charcot-Marie-Tooth disease; neurodegenerative diseases including Parkinson's disease, Lou Gehrig's diseases, Huntington's disease, and HIV dementia; neurotrauma; diabetes, obesity, metabolic syndrome and feeding disorders; solid tumors and leukemia/lymphoma; pain; neuropathies; sleeping disorders and regulation; neuroprotection; and inflammation.